Authors: Markus Bosmann1,2,3,4,* The complement system is an integral part of innate immune defense. It consists of about 50 proteins in plasma, on cell surfaces, and inside host cells. The traditional view is that complement proteins guard the local extracellular spaces and systemic bloodstream against invading pathogens. Loss-of-function mutations resulting in terminal complement pathway deficiencies […]
Authors: Yuichiro J. Suzuki,a,⁎ Sofia I. Nikolaienko,b Vyacheslav A. Dibrova,b Yulia V. Dibrova,b Volodymyr M. Vasylyk,c Mykhailo Y. Novikov,d Nataliia V. Shults,a and Sergiy G. Gychkab Currently, the world is suffering from the pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that uses angiotensin-converting enzyme 2 (ACE2) as a receptor to enter the host cells. So […]
Authors: Gloria F. Gerber,1 Xuan Yuan,1 Jia Yu,1 Benjamin A.Y. Cher,2 Evan M. Braunstein,1 Shruti Chaturvedi,1 and Robert A. Brodsky1,* Complement has emerged as a likely driver of the immune response and end-organ damage in COVID-19. In patients with severe disease, deposition of terminal complement and microthrombosis have been observed in the lung, skin, kidney, and heart.1, 2, 3, 4 Recently, we demonstrated that the severe […]
Authors: Pratibha Anand 1, Vincent P Stahel 2 Abstract The novel coronavirus disease 2019 (COVID-19) has infected more than 100 million people globally within the first year of the pandemic. With a death toll surpassing 500,000 in the United States alone, containing the pandemic is predicated on achieving herd immunity on a global scale. This implies that at […]
Authors: Musha Chen, Yue Yuan, Yiguo Zhou, Zhaomin Deng, Jin Zhao, Fengling Feng, Huachun Zou & Caijun Sun Background Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for […]
Authors: Anne M. Hause, PhD1; Julianne Gee, MPH1; James Baggs, PhD1; Winston E. Abara, MD1; Paige Marquez, MSPH1; Deborah Thompson, MD2; John R. Su, MD, PhD1; Charles Licata, PhD1; Hannah G. Rosenblum, MD1,3; Tanya R. Myers, PhD1; Tom T. Shimabukuro, MD1; David K. Shay, MD1 Summary What is already known about this topic? In preauthorization […]
Authors: Project director: Nikhil K. Mull, MD (CEP), Lead analyst: Matthew D. Mitchell, PhD (CEP), Clinical review: Patrick J. Brennan, MD. (CMO) EVIDENCE SUMMARY: 1. There are no specific guidelines for use of messenger RNA (mRNA) vaccines or contraindications to mRNA vaccines.2. No large trials of any mRNA vaccine have been completed yet.3. The only […]
Authors: C. Ferreras1†, B. Pascual-Miguel1†, C. Mestre-Durán1, A. Navarro-Zapata1, L. Clares-Villa1, C. Martín-Cortázar1, R. De Paz2, A. Marcos2, J. L. Vicario3, A. Balas3, F. García-Sánchez3, C. Eguizabal4,5, C. Solano6, M. Mora-Rillo7, B. Soria8,9 and A. Pérez-Martínez1,10,11* Syndrome coronavirus 2 (SARS-CoV-2) pandemic is causing a second outbreak significantly delaying the hope for the virus’ complete eradication. In the absence of effective vaccines, we need effective treatments with low adverse effects that can […]
Authors: Christina Aungst, PharmD Key takeaways: People who were sick with COVID-19 and recovered might have long-term immunity that lasts for months or years. We don’t know how long vaccine immunity lasts yet, but it is much safer to gain immunity from the vaccine than from getting COVID-19. Experts believe the vaccine will still work […]
Authors: Larissa E van Eijk, 1 , † Mathijs Binkhorst, 2 , † Arno R Bourgonje, 3 , ‡ Annette K Offringa, 4 , ‡ Douwe J Mulder, 5 Eelke M Bos, 6 Nikola Kolundzic, 7 , 8 Amaal E Abdulle, 5 Peter HJ van der Voort, 9 Marcel GM Olde Rikkert, 10 Johannes G van der Hoeven, 11 Wilfred FA den Dunnen, 1 Jan‐Luuk Hillebrands, 1 , § and Harry van Goor 1 , § Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), continues […]